title: Uracil mustard in the treatment of thrombocytosis.
abstract: Uracil mustard was used for the treatment of thrombocytosis in 14 patients, eight who had polycythemia vera and six who had essential thrombocytosis. Intermittent treatment with 1 to 2 mg/day for 14 days was used for most patients, and continuous treatment was used for three patients. The nadir of the platelet count occurred during a mean period of five to seven weeks, and the mean duration between courses was seven months. The drug selectively depressed the platelet count, with a minimal effect on leukocytes and erythrocytes. Uracil mustard is an effective drug for the control of thrombocytosis.
mesh_terms: D000284:Administration, Oral / Q000379:methods; D006801:Humans; D010976:Platelet Count; D011087:Polycythemia Vera / Q000097:blood / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy*; D014499:Uracil Mustard / Q000627:therapeutic use*
chemical_list: D014499:Uracil Mustard